- Latest news▼
-
18:15, May 4 What role does diet plays in the treatment of bipolar disorder?
-
10:52, May 4 Scientists identified dangerous health effects for families with gas cookers in their homes
-
12:36, May 3 Smoking during pregnancy may lead to obese children, study finds
-
10:29, May 3 Scientists discover cell responsible for repairing damaged liver tissue
-
20:17, May 2 NBR: low to moderate intensity exercise protects against depression
-
18:28, May 2 Sixth Armenian International Ophthalmological Conference will be held on 17-19 May
-
16:11, May 2 ВJN: High-fat foods may increase the risk of heart attack and stroke at a young age
-
14:16, May 2 Patterns: Neural network created that models outcome of various patient therapy methods
-
12:05, May 2 Armenia joins Council of Europe convention on protection of patients' rights
-
14:27, May 1 Journal of Neuroscience: Sluggishness of the elderly is due to greater use of calories, research finds
-
10:26, May 1 AstraZeneca admits its Covid vaccine can cause thrombosis
-
19:31, April 30 Scientists calculated how much time per day you should be sitting, standing and sleeping
-
17:37, April 30 The Conversation: Keeping bread in the fridge improves its health benefits
-
14:30, April 30 Frontiers in Molecular Biosciences: Researchers use AI to identify 191 new destructive viruses
-
08:38, April 30 The Guardian: First personalized cancer vaccine developed
All materials
Merck gets EU approval for multiple sclerosis drug
Merck KGaA (MRK.XE) said Friday the European Commission has approved its drug Mavenclad for the treatment of multiple sclerosis.
The German pharmaceuticals company said it expects the drug to become available in Germany and the U.K. as early as September, and that it plans to file for additional regulatory approval in other countries, including the U.S.
Mavenclad 10mg is used to treat highly active relapsing multiple sclerosis. Europe's Committee for Medicinal Products for Human Use had recommended the approval of the treatment in June, the company said.
More than 700,000 people are affected by the neurological desease in Europe and there is no cure available, the company said.
The stock was trading at EUR92.61, up 2.2%.
Follow NEWS.am Medicine on Facebook and Twitter
- Video
- Event calendar
- Archive
- Most read
month
week
day
- 3 women diagnosed with HIV for first time after getting ‘beauty injections’ in US 1279
- AstraZeneca admits its Covid vaccine can cause thrombosis 1238
- Scientists calculated how much time per day you should be sitting, standing and sleeping 1201
- The Conversation: Keeping bread in the fridge improves its health benefits 1189
- The Guardian: First personalized cancer vaccine developed 1178
- In 64% of COVID-19 survivors, the condition worsens after one year 1144
- Ketodiet improved the condition of patients with schizophrenia and bipolar disorder 1037
- Journal of Neuroscience: Sluggishness of the elderly is due to greater use of calories, research finds 1036
- Frontiers in Molecular Biosciences: Researchers use AI to identify 191 new destructive viruses 1032
- Sixth Armenian International Ophthalmological Conference will be held on 17-19 May 994
- 362 cases of measles recorded in Armenia so far in 2024 956
- ECU: body tilt in patients after stroke was found to be curable 905
- Blood: blood cancer drugs may be useful in rheumatoid arthritis 869
- NBR: low to moderate intensity exercise protects against depression 852
- Armenia joins Council of Europe convention on protection of patients' rights 850
- Find us on Facebook
- Poll